Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · February 01, 2018

Efficacy and Safety of SB3 (Trastuzumab Biosimilar) in Patients Treated With Neoadjuvant Therapy for HER2+ Early Breast Cancer

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Journal of Clinical Oncology
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
J. Clin. Oncol 2018 Jan 26;[EPub Ahead of Print], X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, JH Ahn, Y Vinnyk, SA Im, T Sarosiek, S Chatterjee, MZ Wojtukiewicz, V Moiseyenko, Y Shparyk, M Bello, V Semiglazov, S Song, J Lim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated